BASIS OF PRESENTATION AND CHANGE IN ACCOUNTING POLICY (Details Textual) - USD ($) |
1 Months Ended | ||||
---|---|---|---|---|---|
Oct. 29, 2018 |
Feb. 13, 2015 |
Sep. 30, 2018 |
Mar. 31, 2018 |
Mar. 31, 2017 |
|
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 | $ 0.001 | ||
Retained Earnings (Accumulated Deficit) | $ (40,526,427) | $ (35,776,340) | $ (21,076,464) | ||
Stockholders' Equity, Reverse Stock Split | the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014. | ||||
Previously Reported [Member] | |||||
Retained Earnings (Accumulated Deficit) | $ (15,588,554) | ||||
Scenario, Forecast [Member] | |||||
Stockholders' Equity, Reverse Stock Split | the Company effected a reverse stock split and thereafter Bionik’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis. |
X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|